knowledge -WSS

knowledge

author：Wikipedia 2025-10-02 21:35:26 - browse：19945

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How to save PrEP access — and even expand it
Next article： In early work, researchers turn to CRISPR to treat Alzheimer's

WSS

Senate HELP committee spars over health care workforce policies

How Medicaid coverage policies for immigrants impact new moms

FDA panel to weigh approval of NurOwn, controversial ALS drug

Readout LOUD podcast: possible new ALS drug, artificial wombs

Biotech lab space demand falls sharply

Medicare has a new plan to address drug shortages

explore

knowledge

hotspot

Virginia high school admissions case could be legal follow

What Congress can do to address the rural doctor shortage

Dobbs anniversary: the lost opportunity of abortion as health care

Cosmetics set for new safety regulation. Why the industry is on board

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

How dance can help nurses traumatized by Covid

23andMe had bad news about my health. I wish a person had delivered it

Custom gene therapy hints at new path for rare disease treatments

23andMe had bad news about my health. I wish a person had delivered it

Senate HELP committee spars over health care workforce policies

hotspot

As digital health tech proliferates, a new institute aims to cut through hype

How dance can help nurses traumatized by Covid

Custom gene therapy hints at new path for rare disease treatments

Custom gene therapy hints at new path for rare disease treatments

Hearing on Medicare drug price negotiation gets unusually heated

How dance can help nurses traumatized by Covid

explore

Wikipedia

knowledge

entertainment